Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBPW), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is a biopharmaceutical company focused on a patent-pending sublingual delivery platform for drugs, nutraceuticals and supplements. The Aspire Biopharma news feed on Stock Titan brings together company announcements that explain how this platform is being advanced through clinical, regulatory, commercial and capital markets milestones.
Readers can follow detailed updates on Aspire Biopharma’s lead sublingual aspirin program, which the company is developing for the emergency treatment of suspected acute myocardial infarction. News items include results from pilot clinical trials comparing the sublingual aspirin formulation with chewed tablets, reports on rapid platelet inhibition, and disclosures about interactions with the U.S. Food and Drug Administration, such as pre‑IND meetings and regulatory guidance the company has received.
The feed also covers Aspire Biopharma’s corporate and listing developments, including communications about Nasdaq listing status, extensions granted by a Nasdaq Listing Qualifications Panel, transfer of the company’s stock to The Nasdaq Capital Market, and actions such as a 1‑for‑40 reverse stock split intended to help meet minimum bid price requirements. Investors can review how these steps fit into the company’s efforts to maintain its exchange listing and manage its capital structure.
In addition, Aspire Biopharma news highlights commercial activity around BUZZ BOMB™, the company’s proprietary sublingual caffeine supplement. Announcements describe product launches, sampling campaigns at fitness events, new manufacturing relationships, e‑commerce initiatives through a dedicated subsidiary, and brand partnerships such as the appointment of an elite ultra‑runner as a global brand ambassador. Updates on scientific team expansion, patent filings for the sublingual platform, and partnering discussions at major pharmaceutical conferences are also featured.
By reviewing this news stream, users can see how Aspire Biopharma presents the progress of its sublingual technology, from clinical data and regulatory planning to supplement commercialization and financing transactions. The page can be revisited regularly to monitor new press releases and disclosures as they are issued by the company.
Aspire Biopharma (Nasdaq:ASBP) announced a strategic partnership with Microsize to develop a patent-pending, rapid-delivery sublingual alprazolam powder intended to bypass the digestive tract for faster anxiety relief.
Aspire plans a Phase 1 clinical trial in mid-2026, engaged Pace for formulation and stability work, and cites >15.8 million U.S. prescriptions in 2023 and a projected global alprazolam powder market of $55.84 billion by 2032.
Aspire Biopharma (Nasdaq:ASBP) reported a major brand boost for its wholly owned Buzz Bomb Caffeine Company after sponsoring elite runner Ashley Paulson at the 2026 Jackpot Ultra Running Festival.
Key points: Buzz Bomb content surpassed 400,000 views in 48 hours, and Paulson set a new women's 100-mile world record of 12:19:34, with the company citing increased online revenue and consumer acquisition.
Aspire Biopharma (NASDAQ:ASBP) regained full compliance with Nasdaq continued listing requirements on February 20, 2026.
The company met the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and earlier met the $1.00 minimum bid requirement under Rule 5550(a)(2). Nasdaq confirmed the matter is closed, but Aspire will remain under a Panel Monitor through February 18, 2027.
Aspire Biopharma (NASDAQ:ASBP) announced on February 19, 2026 that its subsidiary BUZZ BOMB™ Caffeine Company named ChicExecs as its public relations agency of record as it pursues brand expansion, product innovation, and a comprehensive brand refresh.
ChicExecs will lead media relations, events, strategic partnerships, and PR campaigns to position BUZZ BOMB™—a 50mg sublingual caffeine powder in single-serving stick packs—across food, beverage, fitness, and lifestyle channels.
Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a proprietary sublingual powder formulation of meclizine on February 17, 2026. The formulation targets rapid-onset relief, aiming to cut typical oral onset from about 60 minutes to minutes and to support a 505(b)(2) regulatory path.
The company cites ~4.09 million U.S. prescriptions in 2023 and a $450M global meclizine market, projecting growth to $650M by 2032.
Aspire Biopharma (Nasdaq: ASBP) appointed Phillip Balatsos to its Board of Directors, effective February 6, 2026, following the planned departures of Suren Ajjarapu and Donald G. Fell.
Balatsos brings 25+ years of capital markets and entrepreneurial experience and will serve on the Audit and Compensation Committees, supporting Aspire's strategy to reformulate established drugs using its patent-pending sublingual delivery platform.
Aspire Biopharma (Nasdaq:ASBP) filed a provisional USPTO patent application on February 12, 2026 for a sublingual powder formulation of ondansetron, aimed at rapid relief of chemotherapy-, radiation- and surgery-induced nausea.
The company highlights potential near-instant absorption versus 30-minute oral tablets, plans to pursue an FDA 505(b)(2) pathway, and cites >12.5 million U.S. prescriptions and a ~$1.4B global market (2023).
Aspire Biopharma (Nasdaq:ASBP) entered a securities purchase agreement to sell up to 26,250 Series A convertible preferred shares at $800 per share for aggregate gross proceeds of up to $21.0 million. An initial closing on February 6, 2026 issued 13,750 shares for $11.0 million.
Proceeds will repay legacy indebtedness, support operations and strategic initiatives, and are expected to help the company regain compliance with Nasdaq stockholders' equity requirements. A second closing is subject to customary conditions. RBW Capital Partners acted as sole placement agent.
Aspire Biopharma (Nasdaq: ASBP) regained compliance with Nasdaq Listing Rule 5550(a)(2) after achieving a closing bid of at least $1.00 per share for 10 consecutive business days, and Nasdaq confirmed the matter is closed on February 10, 2026.
The company remains subject to an extension to evidence compliance with the $2.5 million stockholders' equity requirement and says it has made progress on strategic plans for 2026 with additional details to follow.
Aspire Biopharma (NASDAQ:ASBP) subsidiary Buzz Bomb Caffeine Company will showcase its flagship BUZZ BOMB™ sublingual caffeine at The Sports & Active Nutrition Summit USA in San Diego on February 18-20, 2026. The product delivers a rapid 50mg caffeine dose via single-serving stick packs in four flavors and features new branding and a redesigned mobile website for direct purchase.